vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and UPEXI, INC. (UPXI). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $8.1M, roughly 1.6× UPEXI, INC.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -2222.1%, a 2472.8% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 101.0%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs 24.2%).
SPRO vs UPXI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $8.1M |
| Net Profit | $31.5M | $-178.9M |
| Gross Margin | — | 83.3% |
| Operating Margin | — | -2177.9% |
| Net Margin | 250.7% | -2222.1% |
| Revenue YoY | 24080.8% | 101.0% |
| Net Profit YoY | 250.9% | -13649.6% |
| EPS (diluted) | $0.56 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | $8.1M | ||
| Q3 25 | $0 | $9.2M | ||
| Q2 25 | $0 | $4.3M | ||
| Q1 25 | $12.0K | $3.2M | ||
| Q4 24 | $52.0K | $4.0M | ||
| Q3 24 | $65.0K | $4.4M | ||
| Q2 24 | $114.0K | $5.0M | ||
| Q1 24 | $140.0K | $5.2M |
| Q4 25 | $31.5M | $-178.9M | ||
| Q3 25 | $-7.4M | $66.7M | ||
| Q2 25 | $-1.7M | $-6.9M | ||
| Q1 25 | $-13.9M | $-3.8M | ||
| Q4 24 | — | $-1.3M | ||
| Q3 24 | $-17.1M | $-1.6M | ||
| Q2 24 | $-17.9M | $-15.7M | ||
| Q1 24 | $-12.7M | $-4.1M |
| Q4 25 | — | 83.3% | ||
| Q3 25 | — | 89.6% | ||
| Q2 25 | — | 79.4% | ||
| Q1 25 | — | 49.3% | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | — | 67.3% | ||
| Q2 24 | — | 31.0% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | — | -2177.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -151.7% | ||
| Q1 25 | -122758.3% | -113.5% | ||
| Q4 24 | — | -26.8% | ||
| Q3 24 | -28604.6% | -30.6% | ||
| Q2 24 | -16720.2% | -265.2% | ||
| Q1 24 | -9987.1% | -96.5% |
| Q4 25 | 250.7% | -2222.1% | ||
| Q3 25 | — | 722.4% | ||
| Q2 25 | — | -161.5% | ||
| Q1 25 | -115550.0% | -121.2% | ||
| Q4 24 | — | -32.5% | ||
| Q3 24 | -26380.0% | -37.3% | ||
| Q2 24 | -15668.4% | -312.4% | ||
| Q1 24 | -9049.3% | -78.9% |
| Q4 25 | $0.56 | — | ||
| Q3 25 | $-0.13 | $0.76 | ||
| Q2 25 | $-0.03 | $0.83 | ||
| Q1 25 | $-0.25 | $-2.87 | ||
| Q4 24 | — | $-1.24 | ||
| Q3 24 | $-0.32 | $1.55 | ||
| Q2 24 | $-0.33 | $-15.66 | ||
| Q1 24 | $-0.24 | $-4.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $48.7M |
| Total Assets | $68.9M | $271.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | — | ||
| Q3 25 | $48.6M | — | ||
| Q2 25 | $31.2M | — | ||
| Q1 25 | $48.9M | — | ||
| Q4 24 | $52.9M | — | ||
| Q3 24 | $76.3M | — | ||
| Q2 24 | $63.5M | — | ||
| Q1 24 | $82.3M | — |
| Q4 25 | $59.0M | $48.7M | ||
| Q3 25 | $26.5M | $210.8M | ||
| Q2 25 | $32.8M | $90.1M | ||
| Q1 25 | $33.8M | $1.9M | ||
| Q4 24 | $46.1M | $3.8M | ||
| Q3 24 | $65.5M | $5.0M | ||
| Q2 24 | $80.5M | $6.5M | ||
| Q1 24 | $96.2M | $22.1M |
| Q4 25 | $68.9M | $271.1M | ||
| Q3 25 | $54.2M | $419.7M | ||
| Q2 25 | $62.1M | $123.8M | ||
| Q1 25 | $77.7M | $15.1M | ||
| Q4 24 | $110.5M | $17.5M | ||
| Q3 24 | $135.2M | $18.6M | ||
| Q2 24 | $149.9M | $23.5M | ||
| Q1 24 | $167.7M | $56.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.7M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | -0.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-22.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | $-2.7M | ||
| Q3 25 | $17.4M | $-9.8M | ||
| Q2 25 | $-17.7M | $-8.4M | ||
| Q1 25 | $-4.0M | $-778.7K | ||
| Q4 24 | $-23.4M | $-1.4M | ||
| Q3 24 | $12.8M | $-2.0M | ||
| Q2 24 | $-18.7M | $-101.4K | ||
| Q1 24 | $5.9M | $783.5K |
| Q4 25 | — | $-2.7M | ||
| Q3 25 | — | $-9.8M | ||
| Q2 25 | — | $-8.8M | ||
| Q1 25 | — | $-809.3K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $600.9K |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | -106.0% | ||
| Q2 25 | — | -205.4% | ||
| Q1 25 | — | -25.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -20.5% | ||
| Q1 24 | — | 11.5% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 9.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 18.5% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | -0.26× | — | ||
| Q3 25 | — | -0.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
